NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

398.35 -1.30 (-0.33%)

36.89% Gain from 52W Low

2.5M NSE+BSE Volume

NSE 28 Nov, 2025 3:31 PM (IST)

53,257.9

Market Cap

Market Leader

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

26 May 2020

398.35

-0.33%

Axis Alpha - Biocon Ltd (BUY)

Buy: Biocon Ltd.

Target

Axis Direct

We recommend a BUY on Biocon with a Target Price of Rs 385, an upside of ~10% from CMP of Rs. 350 and Stop Loss Rs 332.

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.

Biocon Ltd.

21 May 2020

398.35

-0.33%

BIOCON LTD

Buy: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

The company's medium-term growth outlook remains intact on new product launches and strong pipeline despite challenges amidst COVID19 pandemic. Therefore, we upgrade our rating to BUY on the stock with a revised target price of Rs. 390 based on 31x FY22E adj. EPS. Growth in topline despite Corona-led lockdowns Biocon recorded revenue growth of 3.4% YoY to Rs. 1,581cr, primarily driven by Small molecule segment (+14.6% to Rs. 541cr) on strong growth in generic formulation and steady increase in API sales. Research services business also grew 13.7% YoY to Rs. 607cr backed by robust growth in discovery services and development services. This...

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

18 May 2020

398.35

-0.33%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

Biocon reported a tepid performance for Q4FY20 mainly on account of the one-off impact of the lockdown on the sales of Biologics (including Small Molecules) business; Biologics reported YoY de-growth of ~3% at Rs. 898 cr.

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.

Biocon Ltd.

18 May 2020

398.35

-0.33%

Biocon

Buy: Biocon Ltd.

Recommendation Target

ICICI Securities Limited

The biologics segment (31% of FY20 revenues) includes biosimilars and insulin. The company is heavily spending in this space. The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well. We expect biologics to grow at ~79% CAGR to | 6240 crore in FY20-22E mainly due to a strong US pipeline (Pegfilgrastim (launched), Trastuzumab (launched), Glargine (expected by the end of FY21E), Aspart (expected in FY22E) and...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

16 May 2020

398.35

-0.33%

Earnings plummet led by Biologics???

Neutral: Biocon Ltd.

Motilal Oswal

Nevertheless, BIOS remains confident of achieving its target of USD1b sales by FY22 (from USD270m in FY20), led by new launches and increased market BIOS product development and capacity building for Small Molecules is on track, which should be an additional growth driver over the next 4-5 years. We remain positive on BIOS led by its biosimilar pipeline and capacity enhancement, which should aid market share gain in launched products. The biologics segment, led by potential launches/increased market share gain in existing products and research services (robust business outlook) is expected to drive 38% earnings CAGR for BIOS over FY20-22. BIOS would incur total capex of USD400m over the next 2 years, of which, INR 200b would be in Small Molecules and the rest would be in the Biologics Glargine, Bevacizumab and Aspart provide strong confidence for USD1b Market share of Pegfilgrastim at 6% should grow with capacity expansion.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

12 Feb 2020

398.35

-0.33%

BIOCON LTD

Hold: Biocon Ltd.

Target

Geojit BNP Paribas

The new product launches are expected to drive revenue growth and improve EBITDA margin in the upcoming quarters. However, given the uncertainty concerning supply disruptions from China due to corona virus scare we retain the Hold rating with a revised target price of Rs....

Biocon Ltd. has an average target of 390.50 from 4 brokers.

Biocon Ltd.

24 Jan 2020

398.35

-0.33%

Biocon

Hold: Biocon Ltd.

Recommendation

ICICI Securities Limited

The biologics segment (28% of FY19 revenues) includes biosimilars and insulin. The company is heavily spending in this space. The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia, and Emerging Markets. Post the Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well. We expect biologics to grow at ~57% CAGR to | 5813 crore in FY19-22E mainly due to strong US pipeline [Pegfilgrastim (launched), Trastuzumab (launched), Glargine (expected by the end of FY21E, Aspart (expected in FY22E) and Bevacizumab (expected...

Biocon Ltd. has an average target of 390.50 from 4 brokers.

Biocon Ltd.

30 Oct 2019

398.35

-0.33%

BIOCON LTD

Hold: Biocon Ltd.

Geojit BNP Paribas

While fundamentals remain strong, concerns evolve over regulatory approvals for new facilities post recent FDA observations. We rate the stock a HOLD with target price of Rs. 260 based on ~24x FY21E adj. EPS. Robust revenue growth across segments Consolidated operating revenue grew 19.0% YoY to Rs. 1,572cr, primarily driven by growing revenue from Biologics (+40.4% YoY to Rs. 516cr on higher sales in developed and emerging markets) and Small Molecules segments (+22.6% to Rs. 530cr backed by substantial growth in generic formulations business). Revenue from Research Services...

Biocon Ltd. has an average target of 390.50 from 4 brokers.

Biocon Ltd.

24 Oct 2019

398.35

-0.33%

Biocon

Buy: Biocon Ltd.

Target

ICICI Securities Limited

Revenues grew 19.0% YoY to | 1572.2 crore (I-direct estimate: | 1618.3 crore) mainly due to 40.6% YoY growth in biologics to | 516.1 crore (I-direct estimate: | 513.8 crore). EBITDA margins remained flat YoY at ~25.6% (Idirect estimate: 27.6%). Improvement in gross margins was largely offset by higher other expenditure. EBITDA grew 18.6% YoY to | 402.8 crore against I-direct estimate of | 446.1 crore. Net profit grew a mere 0.5% to | 166.8 crore (I-direct estimate: | 208 crore). Delta vis--vis EBITDA was due...